欧美成人精品三级网站,肥白大屁股bbwbbwhd,国产剧情国产精品一区,精品无人乱码高清在线观看

Wuxi Gotele Metal Products Co., Ltd : CN EN
Home >>News >>News of Medical Acessories

Chinese Cell Therapy Effective in Small Multiple Myelome Trial

Recently, China’s Nanjing Legend Biotech Co. conducted a trial testing the effectiveness of an experimental therapy to treat multiple myeloma. Multiple myeloma is a rate form of blood plasma cancer. The trial proved successful, meaning it induced remission in most patients including those with advanced multiple myelmoa. The trial uses a new drug that utilizes CAR-T therapies, a relatively new medical innovation. 


How It Works

The study run and developed by Nanjing Legend Biotech Co. tested a chimeric antigen receptor T-cell (CAR-T) therapy thirty-five patients. Of the thirty-five nineteen were used in the trial.  Of the nine-teen patients, fourteen reached complete remission after fourth months. The American Society of Clinical Oncology featured the data at their annual meeting. The drug candidate used is known as LCAR-B38M. It is designed to target a protien called BCMA, which is found on cancerous blood plasma cells. CAR-T therapies require a difficult process. It first requires the extraction of immune system T cells from the patient, then their DNA is altered to sharpen their ability to spot and kill cancer cells, lastly the altered cells are infused back into the same patient. Using this technology not only treats the cancer, it offers the possibility for long term remission.  However, there were some negative side effects that came with many patients in the trial. Nearly 85% of patients temporarily developed cytokine release syndrome (CRS). CRS is a potoentially life-threatening inflammatory condition, but the condition was only temporary and easily managed using anti-inflammatory medications.

Continued Use

Due to the positive response experienced by so many in the small trial, China’s Nanjing Legend Biotech Co. hopes to enroll 100 new patients into the trial . They also desire to find other collaborators in the US to conduct a smilar trial in the United States starting as early as 2018.  As of now, two US companies have filed for FDA approval to use CAR-T drugs designed to target different protiens. The FDA will make its decision to approve or dissapprove of these therapies by November 29,2017. If approved CAR-T therapies can be used to treat and induce remission in advanced non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. These advances in medical innovations are putting us one step closer to curing hundreds of diseases and illnesses plaguing millions of people around the world.


HomeTelProductsContact
CN EN
主站蜘蛛池模板: 国产人妻人伦精品1国产丝袜| 国产成人亚洲综合无码18禁h| 97狠狠狠狼鲁亚洲综合网| 国产精品成人精品久久久| 美国一区二区三区无码视频| 插鸡网站在线播放免费观看| 午夜成人理论无码电影在线播放 | 国产欧美在线一区二区三区| 免费女人高潮流视频在线| 国产欧美精品一区二区三区| 精品久久久久久无码人妻| 欧美喷潮久久久xxxxx| 白天躁晚上躁麻豆视频| 欧美深度肠交惨叫| 丁香花在线观看免费观看图片| 亚洲成片在线观看12345| ass日本丰满熟妇pics| 四虎成人国产精品永久在线| 久久婷婷五月综合97色| 国产成人综合亚洲欧美日韩| 日本中文字幕有码在线视频| a∨无码天堂av| 色综合天天无码网站| 欧美老熟妇又粗又大| 日本一区二区三区免费播放| 亚洲男人第一无码av网| 色天使亚洲综合一区二区| 无码全黄毛片免费看| 精品久久久99大香线蕉| 无码av无码天堂资源网| 精品人妻va出轨中文字幕| 日本三级香港三级人妇99| 国产午夜毛片v一区二区三区| 久久国产av影片| 亚洲最大成人网色| 亚洲国产成人av在线观看| 日本三级吃奶头添泬无码苍井空| 日韩好精品视频你懂的| 香港三级韩国三级日本三级| 18禁无遮挡羞羞污污污污网站| 乱码丰满人妻一二三区|